Open Orphan plc changed its name to hVIVO plc on 26 October 2022, learn more here.

11 Sep 2023

Pharma Focus Asia, Issue 52, 2023 – Human Challenge Trials: Establishing early risk-benefit in development of vaccines and therapies for infectious diseases

Share this:

Featured on pages 54-56

Other recent posts

Scientific Paper

Viral emissions into the air and environment after SARS-CoV-2 human challenge: a phase 1, open label, first-in-human study

Effectively implementing strategies to curb SARS-CoV-2 transmission requires understanding who is contagious and when. Although viral load on upper respiratory swabs has commonly been used to infer contagiousness, measuring viral...

Why are Biotech’s & Pharma Using Human Challenge Studies for Drug Development?

What is a human challenge study? In a human challenge study, healthy volunteers are intentionally infected with a virus/bacteria or parasite in a quarantine facility. The volunteers are monitored under...

If you’re a potential customer, job seeker, health professional or an investor, find out how hVIVO can help you.